Skip to main content

Advertisement

Table 1 Patient demographic and baseline characteristics

From: Phase I/II clinical trial of enzyme replacement therapy with idursulfase beta in patients with mucopolysaccharidosis II (Hunter Syndrome)

  Comparator 0.5 mg/kg/week (N=11) Idursulfase beta 0.5 mg/kg/week (N=10) Idursulfase beta 1.0 mg/kg/week (N=10)
Age, years 10.8(±4.6) 11.7(±9) 11.5(±4.7)
Height, cm 124.7(±11.5) 119.6(±10) 122.2(±12.9)
Weight, cm 34.1(±9) 28.6(±7.8) 29.3(±8.9)
Duration of previous ERT, month 14.8(±0.8) 14.3(±0.6) 15.9(±0.7)
Urine GAG*, CPCunit/g Cr 129.1(±59.9) 164(±53.1) 124.7(±36.1)
6MWT, m 368(±76.8) 277.5(±100.2) 328(±70.1)
FVC, L 1.6(±0.5) (N=5) 1.5(±1) (N=3) 1.3(±0.4) (N=4)
LVMI, g/m 2.7 55.6(±15.6) 59.5(±16.3) 54.4(±13.2)
LVEF,% 73.4(±6.7) 68.6(±3.8) 69(±4.1)
  1. *reference range: < 175 CPC unit/g Cr for ≤ 9 years, < 85 CPC unit/g Cr for > 9 years.